This week's roundup of Houston innovators includes Jim Sledzik of Saudi Aramco Energy Ventures, Arti Bhosale of Sieve Health, and Paul Cherukuri of Rice University. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from corporate venture capital to digital health — recently making headlines in Houston innovation.

Jim Sledzik, North American managing director of Saudi Aramco Energy Ventures

Jim Sledzik joins the Houston Innovators Podcast to discuss corporate venture, Houston's role in the energy transition, and more. Photo courtesy of Aramco

When it comes to venture capital, the corporate model can be considered a little less risky, Jim Sledzik, North American managing director of Saudi Aramco Energy Ventures, says on last week's episode of the Houston Innovators Podcast. Over the past decade, Saudi Aramco Energy Ventures has invested $320 million into 33 portfolio companies in the United States. Sledzik, who's worked in various energy services roles around the world before entering in to investment, explains that the corporate venture model is ideal for scaling big technology — and fast.

“When you’re using the venture model in a corporate setting, you have the company and the balance sheet behind you, which brings different benefits to companies you’re investing in,” he says. “These entrepreneurs who are looking to figure out how to deploy technology at scale becomes the real interesting item. All entrepreneurs want to grow — and they want to grow fast."

Scaling fast is risky, but big corporates — like Aramco — can help address the risks by providing a foothold in the market, a place to roll out the technology, and more. Click here to stream the episode and read more.

Arti Bhosale, co-founder and CEO of Sieve Health

Sieve Health is an AI cloud-based SaaS platform designed to automate and accelerate matching patients with clinical trials. Photo

Throughout her career, Arti Bhosale has seen the inefficiency and the ineffectiveness of selecting patients for clinical trials.

“Across the globe, more than 30 percent of clinical trials shut down as a result of not enrolling enough patients,” says Bhosale. “The remaining 80 percent never end up reaching their target enrollment and are shut down by the FDA.”

So, in 2020, Bhosale and her team developed Sieve Health, an AI cloud-based SaaS platform designed to automate and accelerate matching patients with clinical trials and increase access to clinical trials. Click here to read more.

Paul Cherukuri, the inaugural vice president for innovation at Rice University

Meet Paul Cherukuri — the new face of innovation at Rice University. Photo via Rice.edu

Rice University has stood up a new office of innovation — and named its new leader. Paul Cherukuri, the executive director of the Institute of Biosciences and Bioengineering, the inaugural vice president for innovation. In his role, Cherukuri will "lead Rice’s technology and commercialization infrastructure to translate breakthrough discoveries into inventions for the benefit of society," per a news release from Rice.

“I am thrilled and honored to serve in this new role at this inflection point in our university’s history,” Cherukuri says in the release. “Rice has some of the finest minds in the world and I look forward to working with President DesRoches and the leadership team he has assembled to chart a bold new path for world-changing innovation from Rice by engaging the remarkable innovation ecosystem including the Ion District, the Texas Medical Center, industry and other unique assets in Houston.” Click here to read more.

Sieve Health is an AI cloud-based SaaS platform designed to automate and accelerate matching patients with clinical trials. Photo via Getty Images

Houston-based health tech startup is revolutionizing patient selection for clinical trials

working smarter

On many occasions in her early career, Dr. Arti Bhosale, co-founder and CEO of Sieve Health, found herself frustrated with having to manually sift through thousands of digital files.

The documents, each containing the medical records of a patient seeking advanced treatment through a clinical trial, were always there to review — and there were always more to read.

Despite the tediousness of prescreening, which could take years, the idea of missing a patient and not giving them the opportunity to go through a potentially life-altering trial is what kept her going. The one she didn’t read could have slipped through the cracks and potentially not given someone care they needed.

“Those stories have stayed with me,” she says. “That’s why we developed Sieve.”

When standard health care is not an option, advances in medical treatment could be offered through clinical trials. But matching patients to those trials is one of the longest standing problems in the health care industry. Now with the use of new technology as of 2018, the solution to the bottleneck may be a new automated approach.

“Across the globe, more than 30 percent of clinical trials shut down as a result of not enrolling enough patients,” says Bhosale. “The remaining 80 percent never end up reaching their target enrollment and are shut down by the FDA.”

In 2020, Bhosale and her team developed Sieve Health, an AI cloud-based SaaS platform designed to automate and accelerate matching patients with clinical trials and increase access to clinical trials.

Sieve’s main goal is to reduce the administrative burden involved in matching enrollments, which in turn will accelerate the trial execution. They provide the matching for physicians, study sponsors and research sites to enhance operations for faster enrollment of the trials.

The technology mimics but automates the traditional enrollment process — reading medical notes and reviewing in the same way a human would.

“I would have loved to use something like this when I was on the front lines,” Bhosale says, who worked in clinical research for over 12 years. “Can you imagine going through 10,000 records manually? Some of the bigger hospitals have upwards of 100,000 records and you still have to manually review those charts to make sure that the patient is eligible for the trial. That process is called prescreening. It is painful.”

Because physicians wear many hats and have many clinical efforts on their plates, research tends to fall to the bottom of the to-do list. Finding 10-20 patients can take the research team on average 15-20 months to find those people — five of which end up unenrolling, she says.

“We have designed the platform so that the magic can happen in the background, and it allows the physician and research team to get a jumpstart,” she says.” They don’t have to worry about reviewing 10,000 records — they know what their efforts are going to be and will ensure that the entire database has been scanned.”

With Sieve, the team was able to help some commercial pilot programs have a curated data pool for their trials – cutting the administrative burden and time spent searching to less than a week.

Sieve is in early-stage start up mode and the commercial platform has been rolled out. Currently, the team is conducting commercial projects with different research sites and hospitals.

“Our focus now is seeing how many providers we can connect into this,” she says. “There’s a bigger pool out there who want to participate in research but don’t know where to start. That’s where Sieve is stepping in and enabling them to do this — partnering with those and other groups in the ecosystem to bring trials to wherever the physicians and the patients are.”

Arti Bhosale is the co-founder and CEO of Sieve Health. Photo courtesy of Sieve

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

UH lands $1.2M NIH grant to fight superbugs using AI, quantum sensing

drug defense

The fight against antibiotic-resistant bacteria like MRSA is getting science fiction-like upgrades at the University of Houston thanks to a new four-year, $1.26 million grant from the National Institutes of Health.

The university says the recent funding brings total federal support up to $3.5 million for 11 years for the project, which uses AI and quantum-sensing technology to better understand how bacterial proteins develop resistance to drugs.

Any medical professional will tell you that one of the worst things that can happen is almost killing an infection. Bacteria that survive attacks from conventional antibiotic treatments emerge tougher, more resistant and more aggressive than before–making them much harder to treat. A good example is the superbug methicillin-resistant Staphylococcus aureus (MRSA).

UH chemistry professors Yuhong Wang and Shoujun Xu are working on this issue. They know full well that fighting superbugs requires new technology and new approaches, which is what they aim to pioneer with their new grant.

“Drug-resistant bacterial infections such as MRSA are becoming harder to treat, creating an urgent need for faster ways to understand how antibiotics and other small molecules interact with bacterial proteins,” Wang said in a news release.

Wang and Xu’s work centers around GTP, a cellular fuel that can cause tiny changes to a cell's structure when it mutates. Sometimes, those shape changes make it easier for drugs to breach the wall and attack the cells.

The UH scientists are employing AlphaFold, an AI-powered tool that can scan large molecular libraries in seconds. From these models, they can see promising drug combinations for future testing.

Once identified, the team uses their invention, super-resolution force spectroscopy, to monitor the cells. Tiny magnetic beads are attached to genetic material, then magnified to see how strong that material is when pulled. They can measure this incredible microscopic process through an atomic magnetometer, typically used in quantum physics. Combined, all these tools allow a high-definition look at how each molecule might respond to new chemical approaches.

“We're the only chemists in the world that use an atomic magnetometer for biological research,” Xu said. “It's a technique developed by physicists, and there is usually a gap between techniques developed by physicists and biological applications. Yuhong and I have been bridging that gap together for the past 10 years.”

Eventually, Wang and Xu hope to develop powerful software that can be used by drug manufacturers to model cellular responses. With enough predictive data, the software could even get ahead of superbugs’ own mutation, allowing drugs to be developed before new strains arrive.

"We want an algorithm where you input a protein sequence, score the mutation hotspots, and develop new inhibitors before a drug-resistant species even emerges," Wang added.

SpaceX to get more than 700 acres of Texas wildlife refuge in land swap

Space News

A federal judge on Monday, September 21, refused to block the Trump administration from giving SpaceX more than 700 acres of wildlife refuge as part of a land swap in Texas, while environmental groups vowed to continue their legal challenge.

U.S. District Judge Fernando Rodriguez Jr. declined the plaintiffs' request for a preliminary injunction to prevent the parcel exchange, saying they failed to prove it would worsen ecological risks to a Gulf Coast region already transformed by billionaire Elon Musk’s rocket operations.

In June, the U.S. Fish and Wildlife Service approved moving forward with the deal with SpaceX, which would surrender 683 acres the company owns in exchange for the federal land in the Lower Rio Grande Valley National Wildlife Refuge. The 103,000-acre refuge spans four counties along the Texas border and is home to animal habitats and historical landmarks.

Maps show the land SpaceX would acquire would be closer to the company's launchpad near the U.S.-Mexico border.

The swap amounts to a gift of public lands to SpaceX, “clearing the way for bulldozers to tear into this wildlife refuge as soon as next week and turn a public treasure into a private payday,” said Laiken Jordahl, a spokesperson with the Center for Biological Diversity, which filed the lawsuit alongside other opponents including tribal groups. Jordahl said Monday that the litigation will continue even as the exchange goes forward.

“This court order is not the final word. These lands hold incredible spiritual, historical and conservation value for the people and wildlife of South Texas. We won’t stop fighting to keep this irreplaceable public wildlife refuge safe from SpaceX bulldozers,” Jordahl said in a statement.

The lawsuit asks the federal court to halt the exchange, which has worried SpaceX opponents in the area who have long criticized the company's expanding footprint over lost access to beaches and concerns over exploding rockets.

The Fish and Wildlife Service didn’t respond to a request for comment on Monday’s decision. Previously, a spokesperson had said the agency does not comment on ongoing litigation.

The agency issued a final environmental assessment report in June that determined the exchange would cause no significant impact to the area. The report said the federal government believed the acquisition would represent a “net conservation benefit” and provide “substantial long-term conservation value and improving landscape-scale habitat connectivity across refuges in South Texas.”

The judge said that the plaintiffs offered “relatively weak” evidence of environmental harm.

“While they rightfully argue that the preservation of wildlife and historical lands furthers the public interest, they present no evidence demonstrating that the Property will suffer aesthetic, environmental, cultural, or historical degradation during the pendency of this lawsuit,” Rodriguez wrote in his ruling.

In addition, the judge said a preliminary injunction would result in modifications to SpaceX’s development plans, “placing additional hardship on the company’s ability to meet milestones and contractual obligations.”

SpaceX did not return an email seeking comment on the judge's ruling.

The space exploration company first broke ground in Texas more than a decade ago and has expanded rapidly, so much that SpaceX employees last year voted to incorporate their own local government called Starbase.

Rice Alliance, Greentown name winners of Houston Energy and Climate Week pitch competitions

winner winners

Approximately 100 startups from around the world pitched their breakthrough technologies and businesses during Houston Energy and Climate Week, with a select few taking home top prizes and bragging rights.

Each year, investors at the Rice Alliance Energy Technology Venture Forum name the 10 most-promising startups. Greentown's Climatetech Summit also culminates in a pitch event, where member companies can earn cash prizes.

Here's who won at two of the week's anchor events and competitions.

Rice Alliance Energy Tech Venture Forum

The 23nd annual event was held Thursday, Sept. 17, at Rice University’s Jones Graduate School of Business. The most-promising companies were selected by industry experts and participating investors attending the event.

The 10 most-promising companies included:

  • Australia-based Aquafortus, which has developed a non-thermal liquid to liquid desalination technology for resource recovery from wastewater brine
  • Houston-based Focis AI, which converts industrial laser scans into a queryable digital twin of refineries and plants
  • Houston-based ironlattice, a semiconductor manufacturing company
  • Houston-based Licube, which has developed technology to produce ultra-high-purity lithium compounds for the fusion energy, pharmaceuticals, semiconductors and high-performance solid-state battery sectors
  • Houston-based Mars Materials, a clean chemical manufacturing business that is working to convert captured carbon into resources, such as carbon fiber and wastewater treatment chemicals
  • Dallas-based MCatalysis, which has developed a suite of proprietary microwave-driven catalysts to produce high-quality, ready-to-use fuels compatible with existing infrastructure
  • Oslo, Norway-based OTee, an automation machinery manufacturer
  • Houston-based Pike Robotics, which deploys its Wall-Eye robot to inspect hazardous tanks without taking assets offline
  • New Mexico-based Spiritus, a direct-air-capture (DAC) technology company
  • San Francisco-based UptimeAI Inc., which develops AI reasoning agents for industrial operations teams

Stellai won the People's Choice Award. The Norwegian company develops AI products for the waste management industry.

The energy technology ventures selected to participate in the forum were named earlier this year. See the full list here, and read about last year's winners here.

Greentown Lab's Climatetech Summit

The annual summit was held Wednesday, Sept. 16, featured a number of Houston startups in its pitch competition and lighting pitch round. Judges included Dave Dreessen,, Jon Greene, Naval Preet Singh, Philip Llewellyn, Erin Madro, Justin Yeung, Jay Kim, Rawand Rasheed and Moji Karimi.

Pitch winners included:

  • First place: Elementium Materials' CEO Matthew Dawson, winning a $10,000 cash prize sponsored by TotalEnergies plus another $10,000 in legal services sponsored by Foley Hoag. The company develops advanced battery electrolytes. It is a Greentown Boston member; though Dawson is based in Houston.
  • Second place: Houston-based Solidec CEO and co-founder Ryan DuChanois, winning $5,000 in legal services sponsored by Foley Hoag. The company electrolyzes air, water and electricity into onsite hydrogen peroxide.

Lightening pitch winners included:

  • First place: Montana-based MagDrive Technologies, winning a $1,000 cash prize sponsored by Energy Transition Ventures. The company develops magnetically actuated, zero-emission valve systems that eliminate fugitive emissions and improve reliability.
  • Second place: Houston-based HEXASpec, winning a $500 cash prize sponsored by Foley Hoag. The company has created a new material to improve heat management for the semiconductor industry.

Read Greentown's recap of the summit here.

Houston Energy and Climate Week announced that the 2027 event will move to the spring, held April 4-10.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.